Zdrowie i gospodarka · 06/06/2013

FDA Clears Path for Suboxone Sublingual Tablets Approval

The US Food and Drug Administration (FDA) has concluded that Suboxone sublingual tablets, 2mg/0.5mg and 8mg/2mg, were not withdrawn from the market due to safety or efficacy concerns. This decision enables the FDA to potentially approve abbreviated new drug applications for these tablets if all applicable regulations are satisfied.